Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $7.4 billion.

  • UNITED THERAPEUTICS's Liabilities and Shareholders Equity rose 3.20% to $7.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 billion, marking a year-over-year increase of 10.39%. This contributed to the annual value of $7.4 billion for FY2024, which is 2.75% up from last year.
  • As of FY2024, UNITED THERAPEUTICS's Liabilities and Shareholders Equity stood at $7.4 billion, which was up 2.75% from $7.2 billion recorded in FY2023.
  • UNITED THERAPEUTICS's Liabilities and Shareholders Equity's 5-year high stood at $7.4 billion during FY2024, with a 5-year trough of $4.6 billion in FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $7.2 billion (2023), whereas its average is $6.9 billion.
  • Data for UNITED THERAPEUTICS's Liabilities and Shareholders Equity shows a peak YoY rose of 18.57% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Liabilities and Shareholders Equity stood at $4.6 billion in 2020, then grew by 12.01% to $5.2 billion in 2021, then climbed by 16.94% to $6.0 billion in 2022, then rose by 18.57% to $7.2 billion in 2023, then increased by 2.75% to $7.4 billion in 2024.